This company has been marked as potentially delisted and may not be actively trading. Capstar Special Purpose Acquisition (CPSR) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsOwnershipTrendsBuy This Stock CPSR vs. MOR, GMTX, CALT, ZYME, MBX, SBTX, AVTE, NLTX, BIOA, and CYBNShould you be buying Capstar Special Purpose Acquisition stock or one of its competitors? The main competitors of Capstar Special Purpose Acquisition include MorphoSys (MOR), Gemini Therapeutics (GMTX), Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), MBX Biosciences (MBX), Silverback Therapeutics (SBTX), Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), BioAge Labs (BIOA), and Cybin (CYBN). Capstar Special Purpose Acquisition vs. Its Competitors MorphoSys Gemini Therapeutics Calliditas Therapeutics AB (publ) Zymeworks MBX Biosciences Silverback Therapeutics Aerovate Therapeutics Neoleukin Therapeutics BioAge Labs Cybin Capstar Special Purpose Acquisition (NYSE:CPSR) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk. Is CPSR or MOR more profitable? Capstar Special Purpose Acquisition has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Capstar Special Purpose Acquisition's return on equity of 0.00% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets Capstar Special Purpose AcquisitionN/A N/A N/A MorphoSys -226.79%-694.31%-22.55% Does the media favor CPSR or MOR? In the previous week, Capstar Special Purpose Acquisition's average media sentiment score of 0.00 equaled MorphoSys'average media sentiment score. Company Overall Sentiment Capstar Special Purpose Acquisition Neutral MorphoSys Neutral Which has higher valuation & earnings, CPSR or MOR? Capstar Special Purpose Acquisition has higher earnings, but lower revenue than MorphoSys. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCapstar Special Purpose AcquisitionN/AN/A-$15.30MN/AN/AMorphoSys$238.28M11.99-$205.35M-$3.48-5.45 Do institutionals and insiders believe in CPSR or MOR? 64.9% of Capstar Special Purpose Acquisition shares are owned by institutional investors. Comparatively, 18.4% of MorphoSys shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more risk & volatility, CPSR or MOR? Capstar Special Purpose Acquisition has a beta of 0.07, suggesting that its share price is 93% less volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. SummaryCapstar Special Purpose Acquisition beats MorphoSys on 5 of the 8 factors compared between the two stocks. Get Capstar Special Purpose Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for CPSR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CPSR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CPSR vs. The Competition Export to ExcelMetricCapstar Special Purpose AcquisitionPharmaceutical Preparations IndustryMedical SectorNYSE ExchangeMarket Cap$853.42M$868.71M$5.74B$21.57BDividend YieldN/A4.84%5.73%3.49%P/E RatioN/A1.1875.3129.87Price / SalesN/A125.60459.1953.55Price / CashN/A19.5625.8118.13Price / Book-20.966.6613.004.66Net Income-$15.30M-$4.13M$3.29B$999.94M Capstar Special Purpose Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CPSRCapstar Special Purpose AcquisitionN/A$24.740.0%N/A+278.8%$853.42MN/A0.002MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730GMTXGemini TherapeuticsN/A$61.40+2.9%N/A+25.2%$2.66BN/A-61.4030CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ZYMEZymeworks2.48 of 5 stars$14.06+0.4%$21.43+52.4%+25.5%$1.06B$122.87M-9.37460Positive NewsMBXMBX Biosciences2.8387 of 5 stars$14.67+0.7%$37.63+156.5%N/A$492.82MN/A-3.2336Positive NewsSBTXSilverback TherapeuticsN/A$11.12-4.3%N/A-24.6%$400.97MN/A-4.6083High Trading VolumeAVTEAerovate TherapeuticsN/A$7.62-3.5%N/A-88.4%$220.87MN/A-2.5520Positive NewsHigh Trading VolumeNLTXNeoleukin TherapeuticsN/A$19.64+6.3%N/A-54.7%$184.58MN/A-6.3290BIOABioAge Labs0.2017 of 5 stars$4.71+1.3%N/AN/A$168.85M$3.86M0.00N/ACYBNCybin2.687 of 5 stars$5.99-4.0%$85.00+1,319.0%N/A$141.30MN/A-1.3750 Related Companies and Tools Related Companies MorphoSys Competitors Gemini Therapeutics Competitors Calliditas Therapeutics AB (publ) Competitors Zymeworks Competitors MBX Biosciences Competitors Silverback Therapeutics Competitors Aerovate Therapeutics Competitors Neoleukin Therapeutics Competitors BioAge Labs Competitors Cybin Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CPSR) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capstar Special Purpose Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Capstar Special Purpose Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
